Independent HPLC & CoA Verified
COA VerifiedBatch tested for chemical identity, assay purity, sterility, endotoxins and particulate clearance.
Royal Pharma Tirzepatide Research Compound (60mg)
High-capacity 60mg dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist sequence synthesized by Royal Pharma for metabolic signaling pathways, incretin receptor binding affinity, and longitudinal cellular kinetics assays.
Technical Specifications
RUO CertifiedAssay Purity
99.5% Purity (HPLC Verified)
Storage Protocol
-20°C (lyophilized), 4°C (reconstituted)
Format / Concentration
60mg / 2.4mL multiple-dose lyophilized peptide vial
Synthesis Origin
Royal Pharma European Biotech Labs
Access Status
Authorized Researchers Only
Strictly Research Use Only (RUO). Not for diagnostic, veterinary, or human medical procedures. Handled exclusively by authorized laboratory investigators.
Dual GIP / GLP-1 Receptor Agonist Kinetics
Tirzepatide is a 39-amino-acid linear synthetic polypeptide engineered with a C20 fatty diacid moiety enabling albumin binding and dual agonism across glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors.
Synthesized by Royal Pharma as a high-capacity 60mg lyophilized reference vial, each batch is verified via RP-HPLC and Electrospray Ionization Mass Spectrometry (ESI-MS) for sequence fidelity and ≥99.5% analytical purity.
Receptor Class
Dual GIP / GLP-1
Incretin co-agonist sequence
Vial Capacity
60mg Lyophilized
Multi-dose reference format
Purity Standard
99.5% HPLC
ESI-MS molecular mass verified
Synthesized and verified under strict aseptic analytical controls with full batch-level chain-of-custody documentation and independent chromatographic identity release testing.